0000000000085959

AUTHOR

Frank Traub

0000-0002-6400-3257

showing 4 related works from this author

Progress of Phototherapy Applications in the Treatment of Bone Cancer

2021

Bone cancer including primary bone cancer and metastatic bone cancer, remains a challenge claiming millions of lives and affecting the life quality of survivors. Conventional treatments of bone cancer include wide surgical resection, radiotherapy, and chemotherapy. However, some bone cancer cells may remain or recur in the local area after resection, some are highly resistant to chemotherapy, and some are insensitive to radiotherapy. Phototherapy (PT) including photodynamic therapy (PDT) and photothermal therapy (PTT), is a clinically approved, minimally invasive, and highly selective treatment, and has been widely reported for cancer therapy. Under the irradiation of light of a specific wa…

Oncologymedicine.medical_specialtyQH301-705.5Photothermal Therapymedicine.medical_treatmentCancer therapyBone NeoplasmsPhotodynamic therapyReviewCatalysisInorganic ChemistryInternal medicineHumansMedicineBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologySpectroscopyOsteosarcomaChemotherapyPhotosensitizing Agentsbusiness.industryBone cancerOrganic ChemistryCancerbone cancerGeneral MedicinePhototherapyPhotothermal therapymedicine.diseaseComputer Science ApplicationsRadiation therapyChemistryPrimary bonephotodynamic therapyPhotochemotherapyNanoparticlesGoldtumor therapyNeoplasm Recurrence LocalReactive Oxygen SpeciesbusinessInternational Journal of Molecular Sciences
researchProduct

MR Thermometry Data Correlate with Pathological Response for Soft Tissue Sarcoma of the Lower Extremity in a Single Center Analysis of Prospectively …

2020

Background: There is a strong biologic rationale for using locoregional hyperthermia in soft tissue sarcoma and a randomized trial reported significant improvements with hyperthermia. The aim of this study was to describe the opportunities of magnetic resonance (MR)-based thermometry in a cohort of soft tissue sarcoma patients undergoing combined radiotherapy and locoregional hyperthermia. Patients and Methods: For eleven evaluable patients, tumor volume (VTu) and a separate volume for temperature analysis with reliable temperature distribution (Vtherm) were contoured for every hyperthermia treatment (103 therapies). Temperature data were recorded for all tumors and were correlated with cli…

HyperthermiaCancer Researchmedicine.medical_specialtymedicine.medical_treatmentSingle Centerlcsh:RC254-282Article030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineMedicineMR thermometryradiotherapymedicine.diagnostic_testbusiness.industrySoft tissue sarcomaHyperthermia TreatmentSoft tissueMagnetic resonance imagingSarcomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasehyperthermiaRadiation therapyOncology030220 oncology & carcinogenesisSarcomaRadiologybusinesspathological responseCancers
researchProduct

Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases

2021

Simple Summary Metastatic disease remains one of the biggest challenges for tumor therapy. The aim of our study was the preclinical evaluation of adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cell efficacy as a possible treatment strategy for various types of bone metastatic cancers. We confirmed that AdCAR NK-92 cells successfully induces tumor cell lysis in bone metastasis cell lines derived from mammary, renal cell and colorectal carcinoma as well as melanoma in a specific and controllable manner, thus, establishing a potent cellular product with universal applicability and quick clinical translation potential for the treatment of solid tumors, including metastases. Abstract…

0301 basic medicineCancer Researchmedicine.medical_treatmentlcsh:RC254-282ArticleTargeted therapy03 medical and health sciences0302 clinical medicineAntigenNK-92In vivomedicineCytotoxic T celladapterCytotoxicityNK-92bone metastasischimeric antigen receptorbusiness.industryBone metastasissolid tumorsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChimeric antigen receptor030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchbusinessCancers
researchProduct

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma

2021

Simple Summary Osteosarcoma, Ewing’s sarcoma, and H3K27M-mutant diffuse midline glioma are rare but aggressive malignancies occurring mainly in children. Due to their rareness and often fatal course, drug development is challenging. Here, we repurposed the existing drugs dinutuximab and eliglustat and investigated their potential to directly target or indirectly modulate the tumor cell-specific ganglioside GD2. Our data suggest that targeting and/or modulating tumor cell-specific GD2 may offer a new therapeutic strategy for the above mentioned tumor entities. Abstract The ganglioside GD2 is an important target in childhood cancer. Nevertheless, the only therapy targeting GD2 that is approve…

0301 basic medicineCancer Researchlcsh:RC254-282Article03 medical and health sciences0302 clinical medicineNeuroblastomaGliomaosteosarcomaH3K27M-mutant diffuse midline gliomamedicineGangliosidegangliosidebusiness.industrydinutuximabDinutuximabEwing's sarcomaCancerGD2eliglustatlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncologyganglioside; GD2; dinutuximab; eliglustat; miglustat; H3K27M-mutant diffuse midline glioma; Ewing’s sarcoma; osteosarcoma030220 oncology & carcinogenesisCancer researchmiglustatSarcomaEwing’s sarcomabusinessEliglustatCancers; Volume 13; Issue 3; Pages: 520
researchProduct